Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00290290 |
Recruitment Status :
Completed
First Posted : February 13, 2006
Results First Posted : August 11, 2014
Last Update Posted : September 18, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postoperative Wound Infection | Drug: chlorhexidine-alcohol Drug: Povidone-Iodine | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 849 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Chlorhexidine-Alcohol Versus Povidone-Iodine for Surgical-Site Antisepsis:A Prospective, Randomized, Multicenter Clinical Trial |
Study Start Date : | September 2003 |
Actual Primary Completion Date : | May 2008 |
Actual Study Completion Date : | May 2008 |

Arm | Intervention/treatment |
---|---|
Active Comparator: povidone-iodine
preoperative skin preparation with povidone-iodine
|
Drug: Povidone-Iodine
preoperative skin preparation with scrub and paint technique
Other Name: Betadine |
Experimental: chlorhexidine-alcohol
preoperative skin preparation with scrub and paint technique
|
Drug: chlorhexidine-alcohol
Preoperative skin preparation with scrub and paint technique
Other Name: Chloraprep |
- The Primary Objective of This Trial is to Compare the Impact of Disinfecting the Skin With Chloraprep vs. Betadine on the Rates of Infection of Clean-contaminated Surgical Wounds. [ Time Frame: during surgery and within the 30 days post surgery ]The primary end point of the study was the occurrence of any surgical-site infection. Diagnosis of surgical-site infection was diagnosed by a blinded reviewer following criteria developed by the Center for Disease Control. The significance of difference between the two study groups in terms of patient characteristics was determined with the use of the Wilcoxon rank-sum test for continuous variables and Fisher's exact test for categorical variables. For efficacy outcomes, we compared the proportions of patients in the two study groups who could be evaluated and who any type of surgical-site infection using Fisher's exact test and calculating the relative risk of infection and 95% confidence intervals. To determine whether the results were consistent across the 6 participating hospitals, a prespecified Breslow-Day test for homogeneity was performed.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: Adult patients who are scheduled for a clean-contaminated surgical procedure of the alimentary or respiratory tract will be eligible for participation. A clean-contaminated wound is one that is entered under controlled conditions without unusual contamination.
-
Exclusion Criteria: Patients will be excluded form the study if: (1) they are unable or unwilling to give informed consent; (2) the patient is less than 18 years of age; (3) there is evidence of pre-existing infection at or adjacent to the operative site; (4) a break in sterile technique occurs; (5) the patient has a history of allergy to chlorhexidine, alcohol or iodophors.
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00290290
United States, Massachusetts | |
Veterans Affairs Boston Healthcare System | |
West Roxbury, Massachusetts, United States, 02132 | |
United States, North Carolina | |
Durham VA Medical Center | |
Durham, North Carolina, United States, 27705 | |
United States, Texas | |
Ben Taub General Hospital | |
Houston, Texas, United States, 77030 | |
Michael E Debakey Medical Center | |
Houston, Texas, United States, 77030 | |
United States, Wisconsin | |
Medical College of Wisconsin | |
Milwaukee, Wisconsin, United States, 53214 | |
Milwaukee VA Medical Center | |
Milwaukee, Wisconsin, United States, 53214 |
Study Chair: | Rabih O Darouiche, M.D. | Baylor College of Medicine |
Responsible Party: | Rabih Darouiche, Professor of Medicine, Baylor College of Medicine |
ClinicalTrials.gov Identifier: | NCT00290290 |
Other Study ID Numbers: |
H-14542 |
First Posted: | February 13, 2006 Key Record Dates |
Results First Posted: | August 11, 2014 |
Last Update Posted: | September 18, 2014 |
Last Verified: | September 2014 |
Prevention Antiseptic Preoperative Scrub Postoperative Wound Infection |
Infections Wound Infection Surgical Wound Infection Pathologic Processes Postoperative Complications Chlorhexidine Povidone-Iodine |
Povidone Anti-Infective Agents, Local Anti-Infective Agents Disinfectants Plasma Substitutes Blood Substitutes |